Navigation Links
Study Shows Dual Targeting of HER2 and HR-positive Metastatic Breast Cancer Improves Survival Rates
Date:5/7/2013

Durham, NC (PRWEB) May 07, 2013

A new study published in The Oncologist shows targeting both hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) in first-line treatment of metastatic breast cancer (MBC) patients significantly increased overall survival times.

A team of researchers lead by Debu Tripathy, M.D., of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles, CA, looked at data provided by RegistHER, a prospective, observational study of 1,023 newly diagnosed HER2-positive metastatic breast cancer MBC patients. They found that hormonal therapy given with the anti-HER2 antibody trastuzumab (Herceptin) and chemotherapy is associated with improved survival and progression-free survival outcomes, compared to no hormonal therapy.

“This study can aid in significantly improving treatment planning and shared decision-making with patients,” said Dr. Tripathy. “It provides a platform for considering hormonal therapy as a standard component of treatment regimens for patients with HER2-positive and hormone receptor-positive metastatic breast cancer.”

Using data from RegistHER, a multicenter, prospective cohort registry study, the research team determined that the targeting of both hormone and HER2 receptors is associated with better outcomes compared to HER2-based therapy alone. HER2-positive breast cancer, which accounts for approximately 25% of breast cancers diagnosed, tends to be more aggressive than other types of breast cancer because it promotes the growth of cancer cells. About half of HER2-positive breast cancer are also estrogen receptor-positive. Trastuzumab specifically targets HER2 cells and is the standard of care for patients with HER2-positive breast cancer, while HR-positive breast cancer is treated with hormonal therapy designed to interfere with HR signaling.

A lack of uniformity in how hormone therapy is used in treating HER2-positive breast cancer complicates the registry study analysis, but adjustments showed consistent improved progression-free survival times and even overall survival rates, with the addition of hormone therapy to either trastuzumab alone or with chemotherapy.

“This report, although not based on a randomized study, strongly suggests that hormonal therapy is an integral part of the treatment of women with hormone receptor positive, HER-2 positive breast cancer. Randomized designs examining the optimal order of such therapy could add further information to these important data,” said Kathleen I. Pritchard, M.D., FRCPC, Co-Director of the Ontario Clinical Oncology Group (OCOG) at McMaster University and Breast Cancer Section Co-editor for The Oncologist.

###

The full article, titled “First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and HormoneReceptor-Positive Metastatic Breast Cancer From RegistHER,” can be accessed at http://www.TheOncologist.com.

About The Oncologist
Established by oncologists to help physicians better manage their practices in an ever-changing environment, The Oncologist® is the official journal of the Society for Translational Oncology (STO). Now in its 18th year, this internationally peer-reviewed journal focuses on clear and concise interpretation addressing the multimodality diagnosis, treatment, and quality of life of the cancer patient. Each issue is meant to impact the practice of oncology and to facilitate significant communication in the introduction of new medical treatments and technologies. For more information, visit http://www.TheOncologist.com.

About AlphaMed Press: Established in 1983, AlphaMed Press, with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com), which celebrated its 31st year in 2013, is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com), entering its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE® (http://www.StemCellsTM.com), in its second year, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10707150.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Bel Marra Health Reports on a New Study Revealing Why Men Struggle to Figure Out Women
2. Sentimental Gifts Are the Best Mother’s Day Gifts, Study Shows
3. Study examines spiritual support for patients with advanced cancer
4. Living Long May Protect Against Early Alzheimers, Study Finds
5. Flu Vaccine Safe for Kids With Crohns, Colitis: Study
6. Study Links Timing of ER Visit to Prostate Cancer Survival Odds
7. Penn study shows national movement against non-medically indicated deliveries prior to 39 weeks
8. Study shows so-called cougars, sugar daddies more myth than reality
9. Ubiquitous engineered nanomaterials cause lung inflammation, study finds
10. 16 Percent of U.S. High Schoolers Victims of Cyberbullying: Study
11. More Kids Diagnosed With Mental Health Disabilities, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... CA (PRWEB) , ... June 26, 2017 , ... Torrance ... Smile aesthetics can be one of the most noticeable aspects of a person’s appearance. ... While not everyone is born with beautiful, balanced teeth, everyone can have the smile ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced ... hiring of Richard Robinson as chief operating officer (COO). In this role, Robinson ... proven track record of simplifying business processes and developing growth strategies to increase ...
(Date:6/26/2017)... Tahoe, CA (PRWEB) , ... June 26, 2017 , ... ... 10,000 qualified mental health professionals in every state across the country to join its ... easy and rewarding way for therapists to reach a substantially greater number of people ...
(Date:6/26/2017)... ... ... New patients with missing teeth in Fitchburg, WI, can now ... Cotey is a trusted dentist who has placed many dental implants and enjoys teaching ... teeth in Fitchburg, WI, are encouraged to find out if they are candidates for ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United ... replace Obamacare, called the Better Care Reconciliation Act. It differs significantly from the American ... need to be reconciled in committee, or the House will have to take up ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017 Datascope Corp. is voluntarily ... Datascope Corp. for a potential electrical test failure code.     ... PART NUMBER ... IABP CS300 IABP ... ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... and Drug Administration (FDA) has notified the Company that the ... Zhejiang, China manufacturing facility has been closed ... of the Warning Letter related to our ... the progress we have made in our ongoing quality and ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 ... In a further effort to help spread lessons learned ... condition, the International Diabetes Federation (IDF) and Eli Lilly ... together for the second phase of the Bringing Research ... 2), reaffirming their commitment to helping people with diabetes ...
Breaking Medicine Technology: